Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcin
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, name
| Condition(s) | Metastatic Urothelial Carcinoma |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts. |
| Who can participate | Inclusion Criteria: * Patients over 18 years of age * Metastatic urothelial carcinoma * Treated with first-line metastatic therapy since October 2024 Exclusion Criteria: * Patient who expressed opposition to participating in the study |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | University Hospital, Strasbourg, France |
| Locations | Strasbourg, France |
| Start date | 2025-04-20 |
| NCT ID | NCT07339878 |
| Official listing | https://clinicaltrials.gov/study/NCT07339878 |